




Goat F(ab')₂ Anti-Mouse Ig, Human ads

| Cat. No. | Format | Size |
|----------|------------------------------|---------|
| 1012-01 | Purified (UNLB) | 0.5 mg |
| 1012-02 | Fluorescein (FITC) | 0.5 mg |
| 1012-04 | Alkaline Phosphatase (AP) | 1.0 mL |
| 1012-05 | Horseradish Peroxidase (HRP) | 1.0 mL |
| 1012-08 | Biotin (BIOT) | 0.5 mg |
| 1012-09 | R-phycoerythrin (PE) | 0.25 mg |
| 1012-11 | Allophycocyanin (APC) | 0.25 mg |
| 1012-13 | Spectral Red® (SPRD) | 0.25 mg |
| 1012-15 | Cyanine 5 (CY5) | 0.5 mg |
| 1012-30 | Alexa Fluor® 488 (AF488) | 0.5 mg |
| 1012-31 | Alexa Fluor® 647 (AF647) | 0.5 mg |
| 1012-32 | Alexa Fluor® 555 (AF555) | 0.5 mg |



Human pancreatic carcinoma cell line MIA PaCa-2 was stained with Mouse Anti-Cytokeratin 18-UNLB (SB Cat. No. 10085-01; right) followed by Goat F(ab')₂ Anti-Mouse Ig, Human ads-AF555 (SB Cat. No. 1012-32) and DAPI.

Description

| | |
|-------------------------|--|
| Specificity | Reacts with the heavy and light chains of mouse IgG ₁ , IgG _{2a} , IgG _{2b} , IgG _{2c} , IgG ₃ , IgM, and IgA |
| Source | Pepsin digest of Goat Anti-Mouse Ig, Human ads (SB Cat. No. 1010) |
| Cross Adsorption | Human immunoglobulins and pooled sera; may react with immunoglobulins from other species |

Applications

Quality tested applications include –

ELISA ¹⁻⁶
 FLISA
 FC ⁸⁻²¹

Other referenced applications include –

ELISPOT ^{5,7}
 ICC ^{22,23}
 WB ²⁴
 Stim ²⁵⁻²⁷

Working Dilutions

| | | |
|---------------------------|--|--------------------------------|
| ELISA | AP conjugate | 1:2,000 – 1:4,000 |
| | HRP conjugate | 1:4,000 – 1:8,000 |
| | BIOT conjugate | 1:5,000 – 1:20,000 |
| FLISA | FITC, AF488, and AF555 conjugates | 1:100 – 1:400 |
| | PE, APC, CY5, and AF647 conjugates | ≤ 1 µg/mL |
| Flow Cytometry | FITC, BIOT, and AF488 conjugates | ≤ 1 µg/10 ⁶ cells |
| | PE, APC, SPRD, CY5, and AF647 conjugates | ≤ 0.1 µg/10 ⁶ cells |
| | For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL | |
| Other Applications | Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need. | |

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC), Cyanine 5 (CY5), Alexa Fluor® 488 (AF488), Alexa Fluor® 555 (AF555), and Alexa Fluor® 647 (AF647) conjugates are supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl₂/50% glycerol, pH 8.0, containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS, pH 7.4. No preservative added. Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) and allophycocyanin (APC) conjugates are supplied as 0.25 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Spectral Red® (SPRD) conjugate is supplied as 0.25 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

1. Gerth AJ, Lin L, Peng SL. T-bet regulates T-independent IgG2a class switching. *Int Immunol.* 2003;15:937-44. (ELISA)
2. Obie DA, Collett E, Hsieh M, Ambjorn M, Law J, Dutz J, et al. A novel T cell receptor transgenic animal model of seborrheic dermatitis-like skin disease. *J Invest Dermatol.* 2005;124:151-9. (ELISA)
3. Kang T, Oh G, Scandella E, Bolinger B, Ludewig B, Kovalenko A, et al. Mutation of a self-processing site in caspase-8 compromises its apoptotic but not its nonapoptotic functions in bacterial artificial chromosome-transgenic mice. *J Immunol.* 2008;181:2522-32. (ELISA)
4. Seo KY, Han SJ, Cha H, Seo S, Song J, Chung S, et al. Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. *J Immunol.* 2010;185:3610-9. (ELISA)
5. Chang J, Cha H, Chang S, Ko H, Seo S, Kweon M. IFN-γ secreted by CD103⁺ dendritic cells leads to IgG generation in the mesenteric lymph node in the absence of vitamin A. *J Immunol.* 2011;186:6999-7005. (ELISA, ELISPOT)
6. Sun Y, Peng I, Senger K, Hamidzadeh K, Reichelt M, Baca M, et al. Critical role of activation induced cytidine deaminase in experimental autoimmune encephalomyelitis. *Autoimmunity.* 2013;46:157-67. (ELISA)
7. Cha H, Ko H, Kim E, Chang S, Seo S, Cuburu N, et al. Mucosa-associated epithelial chemokine/CCL28 expression in the uterus attracts CCR10⁺ IgA plasma cells following mucosal vaccination via estrogen control. *J Immunol.* 2011;187:3044-52. (ELISPOT)
8. Coccia MA, Brams P. High titer, prostate specific antigen-specific human IgG production by hu-PBL-SCID mice immunized with antigen-mouse IgG2a complex-pulsed autologous dendritic cells. *J Immunol.* 1998;161:5772-80. (FC)
9. Lund FE, Muller-Steffner HM, Yu N, Stout CD, Schuber F, Howard MC. CD38 signaling in B lymphocytes is controlled by its ectodomain but occurs independently of enzymatically generated ADP-ribose or cyclic ADP-ribose. *J Immunol.* 1999;162:2693-702. (FC)
10. Reeb-Whitaker CK, Paigen B, Beamer WG, Bronson RT, Churchill GA, Schweitzer IB, et al. The impact of reduced frequency of cage changes on the health of mice housed in ventilated cages. *Lab Anim.* 2001;35:58-73. (FC)
11. Musso T, Deaglio S, Franco L, Calosso L, Badolato R, Garbarino G, et al. CD38 expression and functional activities are up-regulated by IFN-γ on human monocytes and monocytic cell lines. *J Leukoc Biol.* 2001;69:605-12. (FC)
12. Gildon DR, Howard CJ. CD26 is expressed on a restricted subpopulation of dendritic cells in vivo. *Eur J Immunol.* 2002;32:1472-81. (FC)
13. Bian H, Fournier P, Moormann R, Peeters B, Schirmacher V. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. *Cancer Gene Ther.* 2005;12:295-303. (FC)
14. Richman SA, Healan SJ, Weber KS, Donermeyer DL, Dossett ML, Greenberg PD, et al. Development of a novel strategy for engineering high-affinity proteins by yeast display. *Protein Eng Des Sel.* 2006;19:255-64. (FC)
15. Janke M, Peeters B, de Leeuw O, Moorman R, Arnold A, Fournier P, et al. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. *Gene Ther.* 2007;14:1639-49. (FC)
16. Apostolidis L, Schirmacher V, Fournier P. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. *Int J Oncol.* 2007;31:1009-19. (FC)
17. Sopp P, Werling D, Baldwin C. Cross-reactivity of mAbs to human CD antigens with cells from cattle. *Vet Immunol Immunopathol.* 2007;119:106-14. (FC)
18. Yu KO, Im JS, Illarianov PA, Ndonge RM, Howell AR, Besra GS, et al. Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand α-galactosylceramide bound to mouse CD1d. *J Immunol Methods.* 2007;323:11-23. (FC)
19. Janke M, Peeters B, Zhao H, de Leeuw O, Moorman R, Arnold A, et al. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. *Int J Oncol.* 2008;33:823-32. (FC)
20. Pfirsche C, Schirmacher V. Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. *Int J Oncol.* 2009;34:951-62. (FC)
21. Fournier P, Aigner M, Schirmacher V. Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25. *Int J Oncol.* 2010;37:1439-52. (FC)
22. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. *J Clin Invest.* 2002;109:1453-62. (ICC)
23. Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. *J Immunol.* 2003;171:5537-46. (ICC)
24. Gan M, Moussaud S, Jiang P, McLean PJ. Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction. *Neurobiol Aging.* 2015;36:1209-20. (WB)
25. Do Y, Rafi-Janajreh AQ, Mckallip RJ, Nagarkatti PS, Nagarkatti M. Combined deficiency in CD44 and Fas leads to exacerbation of lymphoproliferative and autoimmune disease. *Int Immunol.* 2003;15:1327-40. (Stim)
26. Liubchenko GA, Appleberry HC, Holers VM, Banda NK, Willis VC, Lyubchenko T. Potentially autoreactive naturally occurring transitional T3 B lymphocytes exhibit a unique signaling profile. *J Autoimmun.* 2012;38:293-303. (Stim)

Spectral Red® is a registered trademark of Southern Biotechnology Associates, Inc.

Spectral Red® is a PE/CY5 tandem conjugate.

Cy® is a registered trademark of GE Healthcare.

Alexa Fluor® 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.

TB1012
03-Jan-21

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com